Department of Urology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, J8.130, Dallas, TX, 75390-9110, USA.
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
World J Urol. 2018 Apr;36(4):645-653. doi: 10.1007/s00345-018-2180-3. Epub 2018 Jan 17.
To evaluate the impact of timing of blood transfusion in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU).
Outcomes of consecutive patients with UTUC treated with RNU were analyzed. Clinicopathologic factors were compared using Fisher's exact test or the Wilcoxon rank-sum test between patients who received any transfusion and no transfusion, and between patients receiving intraoperative transfusion only and patients receiving no transfusion. Cancer-specific and overall survival were estimated and multivariable analyses were performed to assess the impact of timing of transfusion on clinical outcomes.
Among 402 patients included in this study, 71 (17.6%) patients received a transfusion at any point and 27 (6.7%) patients received an intraoperative blood transfusion. Transfusion at any time, patient comorbidity, high grade, advanced stage, positive surgical margins, low preoperative hemoglobin, longer operative duration, and increased blood loss were significantly associated with cancer-specific survival (DSS) on univariable analysis (HR 1.85, 95% CI 1.20-2.85, p < 0.005). In the multivariable analysis, transfusion at any point was not a prognostic factor (HR 1.00, 95% CI 0.60-1.68, p = 0.99). When examining intraoperatively transfusion only, transfusion was significantly associated with DSS (HR 1.91, 95% CI 1.01-3.59, p = 0.045) but no longer significant in multivariable analysis (HR 0.72, 95% CI 0.32-1.65, p = 0.440).
Our study indicates that the administration of blood transfusion either intraoperatively or postoperatively is not associated with clinical or oncological outcomes in patients with upper tract urothelial carcinoma when adjusted for other factors in multivariable analysis. Further study is required.
评估在上尿路尿路上皮癌(UTUC)患者接受根治性肾输尿管切除术(RNU)治疗时输血时机的影响。
分析连续接受 RNU 治疗的 UTUC 患者的临床结果。使用 Fisher 确切检验或 Wilcoxon 秩和检验比较接受任何输血和未输血患者之间以及仅接受术中输血和未输血患者之间的临床病理因素。估计癌症特异性和总体生存率,并进行多变量分析,以评估输血时机对临床结果的影响。
在本研究纳入的 402 例患者中,71 例(17.6%)患者在任何时间点接受输血,27 例(6.7%)患者接受术中输血。在单变量分析中,任何时间点输血、患者合并症、高级别、晚期、阳性切缘、术前低血红蛋白、较长的手术时间和增加的出血量与癌症特异性生存(DSS)显著相关(HR 1.85,95%CI 1.20-2.85,p<0.005)。在多变量分析中,任何时间点输血不是预后因素(HR 1.00,95%CI 0.60-1.68,p=0.99)。当仅检查术中输血时,输血与 DSS 显著相关(HR 1.91,95%CI 1.01-3.59,p=0.045),但在多变量分析中不再显著(HR 0.72,95%CI 0.32-1.65,p=0.440)。
我们的研究表明,在上尿路尿路上皮癌患者中,无论在多变量分析中是否调整了其他因素,术中或术后输血的给予与临床或肿瘤学结果均无相关性。需要进一步研究。